Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Colin Hill

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8226-8566; OpenAlex author ID A5006502149. Sources: OpenAlex.

Their work

Papers
19 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2021: 4 papers · 2022: 10 papers · 2023: 3 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 19

  1. Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Early-Onset Pancreatic Cancer: Clinical Outcomes and Toxicity. Co-author DOI 10.1016/j.ijrobp.2022.07.1120↗
  2. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and … Co-author DOI 10.1016/j.ijrobp.2024.10.039↗
  3. Effectiveness of the nutrition referral system in a multidisciplinary pancreatic cancer clinic. Co-author DOI 10.1007/s00520-023-07795-3↗
  4. The Current Role of Radiation in Pancreatic Cancer and Future Directions. Co-author DOI 10.1016/j.clcc.2023.01.002↗
  5. The Timing of Surgery Following Stereotactic Body Radiation Therapy Impacts Local Control for Borderline Resectable or Locally Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers15041252↗
  6. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients trea… Co-author DOI 10.1002/cam4.4527↗
  7. Efficacy and Safety of Reirradiation with Stereotactic Body Radiation Therapy for Locally Recurrent Pancreatic Adenocarcinoma. First author DOI 10.1016/j.clon.2021.12.014↗
  8. Location, Location, Location: What Should be Targeted Beyond Gross Disease for Localized Pancreatic Ductal Adenocarcinoma? Proposal of a Standardized Clinical … Co-author DOI 10.1016/j.prro.2022.01.005↗
  9. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled… Co-author DOI 10.1016/j.prro.2022.02.009↗
  10. A safety study of intraoperative radiation therapy following stereotactic body radiation therapy and multi-agent chemotherapy in the treatment of localized pan… First author DOI 10.1186/s13014-022-02145-9↗
  11. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderlin… Co-author DOI 10.1245/s10434-021-11202-8↗
  12. High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resecta… First author DOI 10.21037/jgo-21-513↗
  13. Stereotactic body radiation therapy for the treatment of locally recurrent pancreatic cancer after surgical resection. First author DOI 10.21037/jgo-22-38↗
  14. Upfront Chemotherapy Followed by Stereotactic Body Radiation Therapy with or without Surgery in Older Patients with Localized Pancreatic Cancer: A Single Insti… Co-author DOI 10.3390/curroncol29010028↗
  15. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and s… First author DOI 10.3857/roj.2021.01060↗
  16. Geometric Reproducibility of Fiducial Markers and Efficacy of a Patient-Specific Margin Design Using Deep Inspiration Breath Hold for Stereotactic Body Radiati… First author DOI 10.1016/j.adro.2021.100655↗
  17. Fiducial-based image-guided SBRT for pancreatic adenocarcinoma: Does inter-and intra-fraction treatment variation warrant adaptive therapy? Co-author DOI 10.1186/s13014-021-01782-w↗
  18. Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy. Co-author DOI 10.1186/s13014-021-01969-1↗
  19. Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemot… First author DOI 10.3857/roj.2021.00815↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joseph M. Herman · 18 shared papers, 2021–2026 · strength 3.08
  2. Amol Kumar Narang · 18 shared papers, 2021–2026 · strength 2.90
  3. Jin Peng He · 15 shared papers, 2021–2026 · strength 2.42
  4. Abhinav V. Reddy · 13 shared papers, 2021–2026 · strength 2.16
  5. Jeffrey John Meyer · 13 shared papers, 2021–2026 · strength 2.07
  6. Shuchi Sehgal · 13 shared papers, 2021–2026 · strength 2.05
  7. Lei Zheng · 12 shared papers, 2021–2023 · strength 1.83
  8. Amy Hacker‐Prietz · 6 shared papers, 2021–2025 · strength 0.87
  9. Daniel A. Laheru · 5 shared papers, 2022–2025 · strength 0.73
  10. Dung Thi Le · 4 shared papers, 2022–2025 · strength 0.58
  11. Lauren M. Rosati · 3 shared papers, 2022–2025 · strength 0.46
  12. Ana De Jesus‐Acosta · 3 shared papers, 2022 · strength 0.40
  13. Matthew John Weiss · 3 shared papers, 2022 · strength 0.38
  14. Timothy A. Lin · 2 shared papers, 2023 · strength 0.35
  15. Timothy Michael Pawlik · 2 shared papers, 2022–2025 · strength 0.33
  16. Christopher L. Wolfgang · 2 shared papers, 2022–2025 · strength 0.32
  17. S. Han-Oh · 2 shared papers, 2021 · strength 0.28
  18. Ken Kang‐Hsin Wang · 2 shared papers, 2021 · strength 0.28
  19. Matthew John Weiss · 1 shared paper, 2025 · strength 0.20
  20. Lei Zheng · 1 shared paper, 2025 · strength 0.20
  21. Elizabeth M. Jaffee · 1 shared paper, 2025 · strength 0.20
  22. Eric R. Lutz · 1 shared paper, 2025 · strength 0.20
  23. Richard David Schulick · 1 shared paper, 2025 · strength 0.20
  24. Sydnee Wong · 1 shared paper, 2023 · strength 0.17
  25. Atif Zaheer · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.